Met Life Investment Management, LLC Cogent Biosciences, Inc. Transaction History
Met Life Investment Management, LLC
- $18.1 Billion
- Q1 2025
A detailed history of Met Life Investment Management, LLC transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 52,736 shares of COGT stock, worth $624,394. This represents 0.0% of its overall portfolio holdings.
Number of Shares
52,736
Previous 56,750
7.07%
Holding current value
$624,394
Previous $442,000
28.73%
% of portfolio
0.0%
Previous 0.0%
Shares
31 transactions
Others Institutions Holding COGT
# of Institutions
194Shares Held
115MCall Options Held
61.9KPut Options Held
223K-
Kynam Capital Management, LP Princeton, NJ9.11MShares$108 Million4.6% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY8.96MShares$106 Million2.75% of portfolio
-
Commodore Capital LP New York, NY8.89MShares$105 Million5.22% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$86.3 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$82.5 Million10.05% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $779M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...